Risk for second primary ovarian cancer: a large population based on Surveillance, Epidemiology, and End Results database.

IF 2.5 3区 医学 Q3 ONCOLOGY Oncology Pub Date : 2024-11-11 DOI:10.1159/000542044
Haiyang Hu, Yangsheng Ren, Huixing Li, Tishuo Zhang, Lin Sun
{"title":"Risk for second primary ovarian cancer: a large population based on Surveillance, Epidemiology, and End Results database.","authors":"Haiyang Hu, Yangsheng Ren, Huixing Li, Tishuo Zhang, Lin Sun","doi":"10.1159/000542044","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This study aims to evaluate the likelihood of developing a second primary ovarian cancer (OC) considering factors including age, race, and the types of initial malignancies encountered.</p><p><strong>Methods: </strong>This study employed a retrospective cohort approach, compiling data on individuals diagnosed with OC from the Surveillance, Epidemiology, and End Results (SEER) program databases spanning the years 1975 to 2019. The analysis used standardized incidence ratios (SIR) with 95% confidence intervals (CI) to determine the likelihood of developing OC. The result was further refined by categorizing the data based on patient age, race background, first primary cancer types, the time elapsed since the second primary cancer diagnosis, and radiotherapy treatment.</p><p><strong>Results: </strong>A total of 1,536,151 patients with second primary cancer being OC were included. The SIR of the second primary OC was observed to be elevated among patients between the ages of 18 to 64 years (SIR: 1.09, 95% CI: 1.06-1.13). In contrast, for patients who were 65 years of age or older, the SIR for a second primary OC was found to be relatively lower (SIR: 0.87, 95% CI: 0.83-0.91). A lowering, however not statistically significant, of the SIR of the second primary OC in patients with white race was presented. Within 2 months to 1-year diagnosis interval, the SIR of the second primary OC was highest (SIR: 1.48, 95% CI: 1.37-1.61). Liver, gallbladder, intrahepatic, and other bile ducts (SIR: 2.00, 95% CI: 1.38-2.81), and breast cancer (SIR: 1.20, 95% CI: 1.15-1.25) had higher SIRs of second primary OC.</p><p><strong>Conclusion: </strong>This study identifies age, ethnicity, the time span between the diagnoses, and the types of initial cancers as factors correlated with the occurrence of a second primary OC. Our findings suggest that targeted surveillance should be considered for high-risk groups.</p>","PeriodicalId":19497,"journal":{"name":"Oncology","volume":" ","pages":"1-16"},"PeriodicalIF":2.5000,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000542044","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: This study aims to evaluate the likelihood of developing a second primary ovarian cancer (OC) considering factors including age, race, and the types of initial malignancies encountered.

Methods: This study employed a retrospective cohort approach, compiling data on individuals diagnosed with OC from the Surveillance, Epidemiology, and End Results (SEER) program databases spanning the years 1975 to 2019. The analysis used standardized incidence ratios (SIR) with 95% confidence intervals (CI) to determine the likelihood of developing OC. The result was further refined by categorizing the data based on patient age, race background, first primary cancer types, the time elapsed since the second primary cancer diagnosis, and radiotherapy treatment.

Results: A total of 1,536,151 patients with second primary cancer being OC were included. The SIR of the second primary OC was observed to be elevated among patients between the ages of 18 to 64 years (SIR: 1.09, 95% CI: 1.06-1.13). In contrast, for patients who were 65 years of age or older, the SIR for a second primary OC was found to be relatively lower (SIR: 0.87, 95% CI: 0.83-0.91). A lowering, however not statistically significant, of the SIR of the second primary OC in patients with white race was presented. Within 2 months to 1-year diagnosis interval, the SIR of the second primary OC was highest (SIR: 1.48, 95% CI: 1.37-1.61). Liver, gallbladder, intrahepatic, and other bile ducts (SIR: 2.00, 95% CI: 1.38-2.81), and breast cancer (SIR: 1.20, 95% CI: 1.15-1.25) had higher SIRs of second primary OC.

Conclusion: This study identifies age, ethnicity, the time span between the diagnoses, and the types of initial cancers as factors correlated with the occurrence of a second primary OC. Our findings suggest that targeted surveillance should be considered for high-risk groups.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
第二原发性卵巢癌的风险:基于监测、流行病学和最终结果数据库的大型人群。
目的:本研究旨在评估罹患第二次原发性卵巢癌(OC)的可能性:本研究旨在评估罹患第二种原发性卵巢癌(OC)的可能性,考虑的因素包括年龄、种族和初次罹患的恶性肿瘤类型:本研究采用了一种回顾性队列方法,从监测、流行病学和最终结果(SEER)计划数据库中收集了1975年至2019年期间被诊断为卵巢癌患者的数据。分析采用标准化发病率比(SIR)和95%置信区间(CI)来确定罹患OC的可能性。根据患者年龄、种族背景、首次原发性癌症类型、第二次原发性癌症诊断后的时间以及放疗治疗情况对数据进行分类,进一步完善了分析结果:共纳入 1,536,151 名第二原发癌为 OC 的患者。据观察,18 至 64 岁的患者第二次原发肿瘤的 SIR 较高(SIR:1.09,95% CI:1.06-1.13)。相比之下,65 岁或以上的患者第二次原发性 OC 的 SIR 值相对较低(SIR:0.87,95% CI:0.83-0.91)。白人患者第二次原发性 OC 的 SIR 有所降低,但无统计学意义。在 2 个月至 1 年的诊断间隔内,第二原发性肿瘤的 SIR 最高(SIR:1.48,95% CI:1.37-1.61)。肝癌、胆囊癌、肝内胆管癌和其他胆管癌(SIR:2.00,95% CI:1.38-2.81)以及乳腺癌(SIR:1.20,95% CI:1.15-1.25)的第二原发性OC的SIR较高:本研究发现,年龄、种族、诊断之间的时间跨度以及最初癌症的类型与二次原发性卵巢癌的发生相关。我们的研究结果表明,应考虑对高危人群进行有针对性的监测。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Oncology
Oncology 医学-肿瘤学
CiteScore
6.00
自引率
2.90%
发文量
76
审稿时长
6-12 weeks
期刊介绍: Although laboratory and clinical cancer research need to be closely linked, observations at the basic level often remain removed from medical applications. This journal works to accelerate the translation of experimental results into the clinic, and back again into the laboratory for further investigation. The fundamental purpose of this effort is to advance clinically-relevant knowledge of cancer, and improve the outcome of prevention, diagnosis and treatment of malignant disease. The journal publishes significant clinical studies from cancer programs around the world, along with important translational laboratory findings, mini-reviews (invited and submitted) and in-depth discussions of evolving and controversial topics in the oncology arena. A unique feature of the journal is a new section which focuses on rapid peer-review and subsequent publication of short reports of phase 1 and phase 2 clinical cancer trials, with a goal of insuring that high-quality clinical cancer research quickly enters the public domain, regardless of the trial’s ultimate conclusions regarding efficacy or toxicity.
期刊最新文献
Alternative palbociclib dosing schedules for hormone receptor-positive and HER2-negative metastatic breast cancer. Predicting High-Risk Patients with Lung Adenocarcinoma: The Power of Plasma Cell-Related Genes. Characteristics of HCC patients with portal vein thrombosis: albumin and survival. Comparing the efficacy of a triplet antiemetic regimen in patients with esophageal cancer patients and diabetes mellitus treated with cisplatin-based chemotherapy: A retrospective study. Survival outcomes of Durvalumab in combination to cisplatin and gemcitabine in advanced biliary tract cancer: real world results from a single Italian institution.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1